Clinical Study of EVM18001 in the Treatment of Refractory Autoimmune Diseases

A FIH, single arm, open-label, Investigator Initiated Trial (IIT) study to evaluate the safety and tolerability of EVM18001 in the treatment of active refractory autoimmune diseases (SLE, MG, and SSc), and determine the recommended dose for subsequent treatment. At the same time, the PK/PD characteristics of EVM18001 will be evaluated, preliminary efficacy will be observed, and related biomarkers and immunogenicity will be explored.

NCT Number	NCT07470151
Lead Sponsor	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Collaborators: Everest Medicines (China) Co.,Ltd.
Conditions	System Lupus Erythematosus(SLE), Scleroderma, Myasthenia Gravis (MG)
Enrollment	12 participants
Start Date	2026-03-12
Primary Completion	2026-11 (estimated)
Study Completion	2027-12 (estimated)
Updated on ClinicalTrials.gov	2026-03-13